NFL Biosciences Company Description

NFL Biosciences SA, a biotechnology company, engages in the development of natural addiction withdrawal solutions for smokers.

Its pipeline includes NFL-101, a drug candidate for smoking cessation, currently under Phase 2b clinical trials; NFL-201, a drug candidate for cannabis addiction currently in preclinical stage; and NFL-301, a drug candidate for reducing alcohol consumption, currently under in preclinical stage.

The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

NFL Biosciences SA

Country	France
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	2
CEO	Ignacio Faus

Contact Details

Address: 199 Rue HElEne Boucher Castelnau-le-Lez, 34170 France
Phone	33 4 11 93 76 67
Website	nflbiosciences.com

Stock Details

Ticker Symbol	ALNFL
Exchange	Euronext Paris
Fiscal Year	January - December
Reporting Currency	EUR
ISIN Number	FR0014003XT0
SIC Code	2836

Key Executives

Name	Position
Dr. Ignacio Faus M.B.A., Ph.D.	Chief Executive Officer and Chairman
Bruno Lafont M.B.A., M.Sc.	Co-Founder, Chief Operating Officer and Director
Guillaume Audema	Chief Financial Officer